Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)
J.A. Perez-Fidalgo1, A. Cortés2, E. Guerra2, Y. García3, M. Iglesias4, U. Bohn Sarmiento5, E. Calvo García6, L. Manso Sánchez7, A. Santaballa8, A. Oaknin9, A. Redondo10, M.J. Rubio11, A. González-Martín12
1Department of Medical Oncology, Hospital Clínico Universitario de Valencia, Valencia, Spain
2Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain
3Department of Medical Oncology, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT), Universitat Autònoma de Barcelona, Sabadell, Spain
4Department of Medical Oncology, Hospital Son Llatzer, Palma de Mallorca, Spain
5Department of Medical Oncology, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas De Gran Canaria, Spain
6Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Sevilla, Spain
7Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain
8Department of Medical Oncology, Hospital Universitari I Politècnic La Fe, Valencia, Spain
9Department of Medical Oncology, Hospital Universitario Vall d’Hebron, Barcelona, Spain
10Department of Medical Oncology, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain
11Department of Medical Oncology, Hospital Universitario Reina Sofia, Córdoba, Spain
12Department of Medical Oncology Department, Clínica Universidad de Navarra, Madrid, Spain